A/Professor Andrew Redfern describes how findings from the MONALEESA trial program add to the understanding of the place in therapy for the CDK 4/6 inhibitor ribociclib in hormone receptor positive, HER-2 negative advanced breast cancer.

A/Prof Andrew Redfern is Clinical Academic Oncologist, UWA Medical School, University of Western Australia; Haematology-Oncology Discipline Lead, School of Medicine, University of Western Australia; Consultant Medical Oncologist, South Metropolitan Health Service; Medical Director, Linear Clinical Research; Associate Director, Harry Perkins Institute of Medical Research; and Lead Clinician, Breast Tumour Collaborative, WA Cancer & Palliative Care Network

Disclosure

This podcast was sponsored by Novartis. Any views expressed are those of the experts alone and do not necessarily reflect the views of the sponsor. Before prescribing, please review the Kisqali product information here. For PBS information, click here. Treatment decisions based on information in this podcast are the responsibility of the prescribing physician.

Item No: AU-22032. Date of preparation: September 2022